Skip to content

Impact of Quinoa Milk Fermented With Lactic Acid Bacteria From Foods on Human Oral and Intestinal Flora

Impact of Quinoa Milk Fermented With Lactic Acid Bacteria From Foods on Human Oral and Intestinal Flora

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04280731
Enrollment
20
Registered
2020-02-21
Start date
2020-01-07
Completion date
2020-06-20
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microbial Colonization

Brief summary

The demand for alternatives to dairy products has increased in recent years and a lot of proposals for vegetable milk and yogurt products have taken place in the market. Quinoa is a plant from South America that has growth in popularity in recent years as many sought out nutritious and healthier eating, the herb is known for its high nutritional value. It is complete protein source containing all the essential amino acids. If this herb were fermented with probiotic bacteria, there is a potential for a product that is lactose free, gluten free and cholesterol free. The probiotic potential of quinoa milk, fermented with food associated lactic acid bacteria will be investigated. This includes a study that examines how daily consumption of this vegetable drink changes the composition of the oral and intestinal flora. Therefore, healthy people are now seeking to participate in the study, which will be for just over 2 weeks.

Interventions

DIETARY_SUPPLEMENTfermented quinoa

Quinoa drink fermented with lactic acid bacteria isolated from food

Sponsors

Swedish International Development Cooperation Agency (SIDA)
CollaboratorOTHER_GOV
Lund University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Above 18 years and healthy volunteers

Exclusion criteria

* Participants that have any kind of diseases, such as colon inflammation

Design outcomes

Primary

MeasureTime frameDescription
Survivability of the lactic acid bacteria2 weeksIf the bacteria can be isolated in a adequate amount by cultivation on MRS broth and rogosa agar

Secondary

MeasureTime frameDescription
Changes in the human microbiota2 weeksChanges in the saliva and stool samples by analyzes with Terminal Restriction Fragment Length polymorphism

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026